Matteo S. Carlino
Experienced in Hyperthyroidism

Matteo S. Carlino

Cnr Hawkesbury Road And Darcy Road, 
Westmead, NSW, AU 
Experienced in Hyperthyroidism
Cnr Hawkesbury Road And Darcy Road, 
Westmead, NSW, AU 
OverviewLocationsClinical Research

Overview

Matteo Carlino practices in Westmead, Australia. Mr. Carlino is rated as an Experienced expert by MediFind in the treatment of Hyperthyroidism. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Lung Metastases, and Uveal Melanoma.

His clinical research consists of co-authoring 266 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hyperthyroidism.

Gender
Male

Locations

Cnr Hawkesbury Road And Darcy Road, Westmead, NSW 2145, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Biological
Study Phase: Phase 1
An Open-label, Single-arm, Phase I/II, Multicentre Study to Evaluate the Safety and Efficacy of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Unresectable (stage IIIc) and Metastatic (stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma
An Open-label, Single-arm, Phase I/II, Multicentre Study to Evaluate the Safety and Efficacy of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Unresectable (stage IIIc) and Metastatic (stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Radiation, Drug
Study Drug: Dabrafenib and Trametinib (Combination)
Study Phase: Phase 1/Phase 2
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Enrollment Status: Unknown
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Pembrolizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

266 Total Publications

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma.
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Carlino's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile